<DOC>
	<DOC>NCT00989092</DOC>
	<brief_summary>This phase 2, multicenter, randomized, open-label, comparative study was designed to determine the effect of darbepoetin alfa on hospital days, economic outcomes, and health related quality of life (HRQOL) in anemic patients with nonmyeloid malignancies who were not receiving chemotherapy. Participants were randomly assigned in a 4:1 allocation ratio to receive either 21 weeks of darbepoetin alfa treatment (treatment group) or 12 weeks of observation followed by up to 9 weeks of darbepoetin alfa treatment (observation group).</brief_summary>
	<brief_title>Darbepoetin Alfa and Anemia of Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>nonmyeloid malignancies (including lymphocytic leukemias) anemia (hemoglobin concentration less than or equal to 11.0 g/dL) due to cancer and/or previous chemotherapy or radiotherapy Eastern Cooperative Oncology Group performance status of 0 to 2 adequate liver and renal functions 18 years or older history of recombinant human erythropoietin therapy, cytotoxic chemotherapy, or more than 30 Gy radiotherapy to the whole pelvis within 4 weeks before screening acute myelogenous leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome known hematologic disorders that could cause anemia inflammatory or cardiac disorders previous positive antibody response to any erythropoietic agent history of pure red cell aplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>anemia of cancer</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Aranesp</keyword>
</DOC>